332179-69-8

Basic information

• Product Name: 7-chloro-2,5-dimethyl-3-(2,4-dimethoxyphenyl)-pyrazolo[1,5-a]pyrimidine
• Synonyms: 7-chloro-2,5-dimethyl-3-(2,4-dimethoxyphenyl)-pyrazolo[1,5-a]pyrimidine
• CAS NO: 332179-69-8
• Molecular Weight: 317.775
• Mol File: 332179-69-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 7-chloro-2,5-dimethyl-3-(2,4-dimethoxyphenyl)-pyrazolo[1,5-a]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-chloro-2,5-dimethyl-3-(2,4-dimethoxyphenyl)-pyrazolo[1,5-a]pyrimidine(332179-69-8)
• EPA Substance Registry System: 7-chloro-2,5-dimethyl-3-(2,4-dimethoxyphenyl)-pyrazolo[1,5-a]pyrimidine(332179-69-8)

Safety Data

• Hazardous Substances Data: 332179-69-8(Hazardous Substances Data)

Upstream product

• 863550-42-9 4-(2,4-dimethoxy-phenyl)-5-methyl-2H-pyrazol-3-ylamine 
• 332179-40-5 2-(2,4-dimethoxyphenyl)-3-oxobutanenitrile 
• 1891-11-8 (2,4-dimethoxyphenyl)acetonitrile 
• 863550-43-0 7-Hydroxy-2,5-dimethyl-3-(2,4-dimethoxyphenyl)-pyrazolo[1,5-a]pyrimidine 

Downstream Products

• 863550-35-0 2,5-dimethyl-3-(2,4-dimethoxy-phenyl)-7-(diethylamino)pyrazolo[2,3-a]pyrimidine 
• 1098432-05-3 7-(2-aminoethylamino)-2,5-dimethyl-3-(2,4-dimethoxyphenyl)-pyrazolo[1,5-a] pyrimidine 
• 885221-01-2 C₂₂H₂₈N₄O₅ 
• 195055-82-4 C₁₉H₂₄N₄O₃ 
• 332178-33-3 7-(2-(2-(4-ethoxy-3-methoxyphenyl)ethylamino)ethylamino)-3-(2,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine 

Relevant articles and documents

PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility

In our efforts to identify potent CRF1 antagonists with proper physicochemical properties, a series of 3-phenylpyrazolo[1,5-a]pyrimidines bearing polar groups, such as amino, hydroxyl, methoxy, sulfoxide, were designed and synthesized. Several positions of the core structure were identified, where a polar group was tolerated with slight reduction in receptor binding. NBI 30545 (18n) was found to have good binding affinity and potent antagonistic activity at the human CRF1 receptor. Moreover, this compound had proper lipophilicity (logD=2.78) and good solubility in water (>10mg/mL), and exhibited good plasma and brain exposure when given orally.